ITPRIPL1 binds CD3epsilon to impede T cell activation and enable tumor immune evasion. (https://pubmed.ncbi.nlm.nih.gov/38614099/)

These scientists discovered a new protein called ITPRIPL1 that stops our immune system from fighting cancer effectively. They found that this protein prevents our immune cells, called T cells, from getting activated and attacking cancer cells. By using a special antibody that blocks ITPRIPL1, they were able to make the immune system stronger and better at fighting tumors in both mice and dogs. This study shows that targeting ITPRIPL1 could be a promising way to help our bodies fight against different types of cancer.

Deng S., Zhang Y., Wang H., Liang W., Xie L., Li N., Fang Y., Wang Y., Liu J., Chi H., Sun Y., Ye R., Shan L., Shi J., Shen Z., Wang Y., Wang S., Brosseau JP., Wang F., Liu G., Quan Y., Xu J. ITPRIPL1 binds CD3epsilon to impede T cell activation and enable tumor immune evasion. Cell. 2024 Apr 25;187(9):2305-2323.e33. doi: 10.1016/j.cell.2024.03.019. Epub 2024 Apr 12.